Welcome!

News Feed Item

Diabetes - KOL Insight and Consensus Outlook Modules

NEW YORK, Feb. 13, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Diabetes – KOL Insight and Consensus Outlook Modules
http://www.reportlinker.com/p01658957/Diabetes-–-KOL-Insight-and-Consensus-Outlook-Modules.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Introduction

The medium term: battle lines are drawn
The fundamental drivers of the global diabetes market are strong and continue to fuel growth. Rising levels of obesity and disease prevalence in both established and emerging markets have seen the sector return a 5 year compound annual growth rate (CAGR) of 12% over to reach US$31.9 billion in 2012. It is estimated that 347 million people have the disease – 90% of whom are Type II diabetes sufferers – and this figure could almost double by 2030.

The big four companies in diabetes - Novo Nordisk, Sanofi, Eli Lilly and Merck – are locked in a battle of supremacy which is set to continue over the medium term. While Novo Nordisk currently leads the pack, Sanofi is close behind. With Novo Nordisk's approval of Tresiba (insulin degedec) stalled in the US over safety concerns, Sanofi latest version of Lantus U300 (insulin glargine)) could capitalise. Bristol Myers-Squibb and AstraZeneca are just two of the other players set to increase their sales significantly in this busy market place by 2017.

The diabetes market will continue on an upward trajectory, and an estimated 5 year CAGR of 11 percent will see the sector top US$54 billion – the question is which companies will have a slice to this market, and how big will it be?

What's in the pipeline?
Finding market voice for new products in diabetes depends critically on price and differentiation. Cost of treatment is already an issue and resistance can be expected from health payers if new products offer only marginal therapeutic or patient management benefits. For example, excitement about Sanofi's U300 (insulin glargine) is because it shows differentiation to Lantus with "peakless" delivery and longer duration. Eli Lilly's weekly dose dulaglutide may offer advantages over other launched and pipeline GLP-1 products such as such as GSK's Eperzan (albiglutide) and BMS/AZ/Amylin's Bydureon (exanatide) but meaningful advantages need to be shown for success in the market.


What the Future Holds: is there a Game Changer on the Horizon?
Don't expect a revolution in diabetes treatment soon. New products coming to market are essentially incremental improvements over current approaches, with better safety profiles and geared to improving patient compliance.

The real prize will be for the company that can bring a paradigm shift to the treatment of diabetes. Upsetting the status quo will require a fundamentally different approach - and some of these developments threaten the diabetes drugs manufacturers existing revenues.

Among the developments to be aware of are the threat of biosimilars, the development of an artificial pancreas 'closed loop' system, the wide implementation of which would be a doomsday development for drugs companies, and a DNA reverse vaccine for which early clinical results have shown promising results.


A Complete Ongoing Analysis of Current Trends, Future Forecasts and Landscape Modifiers
For instant access to an accurate, unbiased, qualitative review of the latest treatment trends along with a five-year quantitative diabetes market forecast look no further than FirstWord's Therapy Trends: Diabetes. This comprehensive FirstWord research is available in two comprehensive modules:

• The KOL Insight: Diabetes module provides a complete review and is enhanced with exclusive in-depth interviews with leading KOLs from the US and Europe
• TThe Consensus Outlook: Diabetes data analysis module provides annual historical and forecast product-level sales data from an average of leading equity analysts' projections


Scope


KOL Insight
Therapy Trends KOL Insight: Diabetes analyses the current and predicted key issues, current products and late-stage pipeline products. The report gives you qualitative, inside information from exclusive FirstWord interviews with 12 key opinion leaders (KOLs) through the following:

• KOL Insight Report — an in-depth analytical report on diabetes treatment trends
• Full report updates — issued to you after each and every significant diabetes market event
• Event Bulletins — the latest KOL views in response to each event


Key Report Features and Benefits

• Critical insights on products and market developments from leading US and European clinicians

• Complete coverage of all sub sectors - Basal, Prandial and Premixed insulins, DPP-IV inhibitors, GLP-1 agonists/analogues, SGLT-2 inhibitors, Thiazolidinediones and other non insulin anti diabetics
• Assessment of current leading diabetes products by sub sector
• Analysis of late-stage pipeline diabetes therapies by sub sector
• Competitive evaluation of leading players
• Current thinking and trends in the treatment of diabetes
• Predicted KOL treatment trends and market leaders
• Ongoing FirstWord clinical and market updates


Expert Opinion for Real World Insights
The data and analysis in the report is enriched through the specific insights and opinions of leading clinicians working in diabetes in the US and Europe. Their views on specific drugs and treatment pathways provide a unique front line perspective from those working in clinical setting. The results of these detailed and extensive interviews are incorporated though out the text so they can be read in the context of the issue or product being discussed.

US KOLs

• Dr Elif Oral, MD, Associate Professor of Endocrinology, University of Michigan, Ann Arbor, MI.

• Dr Sonal Singh, MD, MPH, Assistant Professor, Division of General Internal Medicines, John Hopkins University, Baltimore, MD.

• Dr Carol Wysham, MD, Clinical Associate Professor of Medicine, Division of General Internal Medicines, University of Washington School of Medicine, Washington.

• Dr Joel Zonszein, MD, Director of the Clinical Diabetes Center at the University Hospital Albert Einstein College of Medicine, a Division of Montefiori Medical Center, NY.

• Requested anonymous, Associate Professor of Medicine, Endocrinology and Metabolism, Duke University, Durham, NC.


European KOLs


• Professor Bernard Charbonnel, MD, Professor of Endocrinology and Metabolic Diseases, University of Nantes; Head of the Internal Medicine, Endocrinology and Diabetes Department, Hôtel Dieu, University Hospital of Nantes, France.
• Professor Melanie Davies, MD, Honorary Consultant, Diabetes, University Hospital Leicester, Leicestershire, UK.
• Professor Marc Donath, MD, Director, Endocrinology, Diabetes and Clinical Nutrition, University Hospital, Basel, Switzerland.
• Professor Baptist Gallwitz, MD, Professor, Professor of Medicine, Diabetes, Eberhard Karls University, University Hospital of Tuebingen, Germany.
• Professor Jens Holst, MD, Professor of Medical Physiology, Department of Biomedical Sciences; Director of the Research Cluster for Diabetes and Obesity; Vice Chairman, Faculty of Health Sciences, University of Copenhagen, Denmark.
• Professor Michael Nauck, MD, Head, Diabeteszentrum Bad Lauterberg, Harz, Germany.
• Professor John Wilding, MD, Head of the Department of Obesity and Endocrinology, University of Liverpool, UK.


Key Quotes from the Report
"I like Janumet. I get a much more effective medication even in one pill a day using combination therapy. Janumet has this long acting glycol, so it is long acting. In early diabetes, together with lifestyle changes, I often use a combination of DPP-IV with metformin, either once or twice a day because it doesn't cause hypoglycaemia. The patients don't need to monitor their blood sugar three, four, five times a day. They don't get admitted to the hospital with hypoglycaemia so the side effects are low. So I start treating these patients with a combination therapy, like Janumet." Dr Joel Zonszein (US)
"I think lots of people use Kombiglyze because it improves compliance so it makes sense. In the therapeutic armamentarium it's the only real once daily combination." Professor Sonal Singh (US)
"In terms of efficacy, side effects, convenience and device, Victoza is the preferred GLP-1. If I look at the new-starts, probably 60 percent of people are going for the Victoza" Dr Carol Wysham (US)
"The prevention of hypoglycaemia is a very important aim for the classical drugs and an unmet need. We should be searching for alternatives to insulin." Professor Baptist Gallwitz (EU)
"I am not too optimistic that you can improve DPP-IV inhibitors to be more efficacious. You may well be able to improve GLP-1 agonists to have more efficacious drugs that have less side effects based on the variety within the class that we have seen until now. I think that the pharmaceutical industry as a whole is a little bit running out of ideas, so we really need to identify good targets." Professor Michael Nauck (EU)
"I think if someone came up with a reasonably well-tolerated drug that helped you lose weight [and] that you only had to take once a month or once a year? Everyone would be on that. US Key Opinion Leader
"Our local insurance company have taken all of what they consider tier 3 drugs, and they include all the GLP-1 agents including the DPP-IV inhibitors, and just put them on a 50-percent co-pay. Fifty percent of a lot of money is still a lot of money." Dr Carol Wysham (US)

KOL Insights -- Key Topics

• Current diabetes marketplace

• Epidemiology

• Aetiology

• Diagnosis

• Current treatment landscape

• Reimbursement of key diabetes brands

• Current marketed therapies

• Pipeline therapies

• Unmet needs

• Current treatment algorithm

• Future treatment algorithm

• Future developments in Diabetes


Consensus Outlook
Use this detailed report and powerful interactive Excel spreadsheet to compare and contrast companies and products now and in the future. Therapy Trends Consensus Outlook: Diabetes includes the following comprehensive resources:



• An in-depth forecast report based on consensus figures from 13 leading analysts. Rich in tables and charts, the report maps the impact of future events to predict product and company performance
• An interactive forecast data analysis spreadsheet comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017
• Timely event-driven market forecast report and data analysis updates over 12 months


Report features:

• Historical diabetes sales from 2007–2012
• Forecast diabetes sales from 2013-2017
• Key competitors and drug developers
• Current and late-stage pipeline drugs
• Future event mapping to forecast data points
• Expected impacting factors on global forecasts



Use Consensus Outlook to:

• •Chart predicted market growth and product sales
• Map your own market parameters
• Tailor your strategic and investment focus
• Assess your current and future sales resources
• Set proactive launches and branding strategies



Analysts compared:

• Barclays Capital
• Credit Suisse
• Deutsche Bank
• Goldman & Sachs
• International Strategy & Investment
• Jefferies
• JP Morgan
• Merrill Lynch
• Morgan & Stanley
• Societe Generale
• Stifel Nicolaus
• UBS
•Wells Fargo





Highlights


Content Highlights and Products Covered:

• Research Methodology
• Diabetes Marketplace
• Key Diabetes Developers
• Diabetes Class Dynamics
• Lantus (insulin glargine; Sanofi) forecast
• Levemir (insulin detemir; Novo Nordisk) forecast
• Tresiba (insulin degludec; Novo Nordisk) forecast
• Ryzodeg (degludecPlus; Novo Nordisk) forecast
• NovoRapid/NovoLog (insulin aspart; Novo Nordisk) forecast
• Humalog (insulin lispro; Eli Lilly) forecast
• Apidra (insulin glulisine; Sanofi) forecast
• NovoMix/NovoLog Mix (insulin aspart + insulin aspart protamine; Novo Nordisk) forecast
• Januvia franchise (sitagliptin; Merck & Co) forecast
• Galvus franchise (vildagliptin; Novartis) forecast
• Onglyza franchise (saxagliptin; Bristol-Myers Squibb/AstraZeneca/ Otsuka) forecast
• Nesina franchise (alogliptin; Takeda) forecast
• Tradjenta franchise (linagliptin; Boehringer Ingelheim/Eli Lilly) forecast
• Byetta (exenatide; Bristol-Myers Squibb/AstraZeneca/Amylin) forecast
• Bydureon (exenatide once-weekly; Bristol-Myers Squibb/AstraZeneca/ Amylin) forecast
• Victoza (liraglutide; Novo Nordisk) forecast
• Lyxumia (lixisenatide; Sanofi) forecast
• Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe) forecast
• Forxiga (dapagliflozin; Bristol-Myers Squibb/AstraZeneca) forecast
• Actos (pioglitazone; Takeda) forecast
• U300 (insulin glargine; Sanofi) forecast
• LY2605541 (insulin peglispro; Eli Lilly) forecast
• LY2963016 (biosimilar insulin glargine; Eli Lilly/Boehringer Ingelheim) forecast
• IDeglira (liraglutide + insulin degludec; Novo Nordisk) forecast
• Afrezza (Technosphere Insulin; MannKind Corporation) forecast
• FIAsp (insulin aspart; Novo Nordisk) forecast
• Eperzan (albiglutide; GlaxoSmithKline/Human Genome Sciences) forecast
• LY2189265 (dulaglutide; Eli Lilly) forecast
• BI-10773 (empagliflozin; Boehringer Ingelheim/Eli Lilly) forecast



Contents Consensus Outlook
1.FirstWord Analysis Highlights
2.Research Methodology
3.Diabetes Marketplace
4.Key Diabetes Developers
5.Diabetes Class Dynamics
6.Lantus (insulin glargine; Sanofi) forecast
7.Levemir (insulin detemir; Novo Nordisk) forecast
8.Tresiba (insulin degludec; Novo Nordisk) forecast
9.Ryzodeg (degludecPlus; Novo Nordisk) forecast
10.NovoRapid/NovoLog (insulin aspart; Novo Nordisk) forecast
11.Humalog (insulin lispro; Eli Lilly) forecast
12.Apidra (insulin glulisine; Sanofi) forecast
13.NovoMix/NovoLog Mix (insulin aspart + insulin aspart protamine; Novo Nordisk) forecast
14.Januvia franchise (sitagliptin; Merck & Co) forecast
15.Galvus franchise (vildagliptin; Novartis) forecast
16.Onglyza franchise (saxagliptin; Bristol-Myers Squibb/AstraZeneca/ Otsuka) forecast
17.Nesina franchise (alogliptin; Takeda) forecast
18.Tradjenta franchise (linagliptin; Boehringer Ingelheim/Eli Lilly) forecast
19.Byetta (exenatide; Bristol-Myers Squibb/AstraZeneca/Amylin) forecast
20.Bydureon (exenatide once-weekly; Bristol-Myers Squibb/AstraZeneca/ Amylin) forecast
21.Victoza (liraglutide; Novo Nordisk) forecast
22.Lyxumia (lixisenatide; Sanofi) forecast
23.Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe) forecast
24.Forxiga (dapagliflozin; Bristol-Myers Squibb/AstraZeneca) forecast
25.Actos (pioglitazone; Takeda) forecast
26.U300 (insulin glargine; Sanofi) forecast
27.LY2605541 (insulin peglispro; Eli Lilly) forecast
28.LY2963016 (biosimilar insulin glargine; Eli Lilly/Boehringer Ingelheim) forecast
29.IDeglira (liraglutide + insulin degludec; Novo Nordisk) forecast
30.Afrezza (Technosphere Insulin; MannKind Corporation) forecast
31.FIAsp (insulin aspart; Novo Nordisk) forecast
32.Eperzan (albiglutide; GlaxoSmithKline/Human Genome Sciences) forecast
33.LY2189265 (dulaglutide; Eli Lilly) forecast
34.BI-10773 (empagliflozin; Boehringer Ingelheim/Eli Lilly) forecast


KOL Insights
1.summary
2.Introduction
3.Methodology
4.Current diabetes marketplace
5.Diabetes overview
5.1.Diabetes definition
5.2.Diabetes segmentation
5.3.Epidemiology
5.4.Aetiology
5.5.Risk factors
5.6.Symptoms
5.7.Complications of diabetes
5.8.Diagnosis
5.9.Diabetes treatment
5.10.Current treatment landscape
5.11.Reimbursement of key diabetes brands
6.Current marketed therapies
6.1.Basal insulins
6.2.Prandial insulins
6.3.Premixed insulins
6.4.Dipeptidyl Peptidase-IV (DPP-IV) inhibitors
6.5.Glucagon-like peptide-1 (GLP-1) agonists/analogues
6.6.Sodium-glucose co-transporter-2 (SGLT-2) inhibitors
6.7.Thiazolidinediones (TZD)
6.8.Other non-insulin anti-diabetics
7.Pipeline therapies
7.1.Pipeline basal insulins
7.2.Pipeline prandial insulins
7.3.Pipeline dipeptidyl peptidase-IV (DPP-IV) inhibitors
7.4.Pipeline glucagon-like peptide-1 (GLP-1) agonists/analogues
7.5.Pipeline sodium-glucose co-transporter 2 (SGLT-2) inhibitors
7.6.Other pipeline non-insulin anti-diabetics
8.Treatment focus
8.1.Unmet needs in type 1 diabetes
8.2.Unmet needs in type 2 diabetes
8.3.Current treatment algorithm- Type2 diabetes
8.4.Future treatment algorithm
9.Future developments in Diabetes
9.1.Biosimilar insulin commercial threat limited
9.2.Continuous glucose monitoring and closed loop systems
9.3.Transplantation or regeneration of beta-cells
9.4.Targeting immune response and inflammation
10.Appendix
10.1.KOL biographies




To order this report: Diabetes – KOL Insight and Consensus Outlook Modules
http://www.reportlinker.com/p01658957/Diabetes-–-KOL-Insight-and-Consensus-Outlook-Modules.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

 

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his opening keynote at 20th Cloud Expo, Michael Maximilien, Research Scientist, Architect, and Engineer at IBM, discussed the full potential of the cloud and social data requires artificial intelligence. By mixing Cloud Foundry and the rich set of Watson services, IBM's Bluemix is the best cloud operating system for enterprises today, providing rapid development and deployment of applications that can take advantage of the rich catalog of Watson services to help drive insights from the vast t...
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
For financial firms, the cloud is going to increasingly become a crucial part of dealing with customers over the next five years and beyond, particularly with the growing use and acceptance of virtual currencies. There are new data storage paradigms on the horizon that will deliver secure solutions for storing and moving sensitive financial data around the world without touching terrestrial networks. In his session at 20th Cloud Expo, Cliff Beek, President of Cloud Constellation Corporation, d...
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reduction in cost ...
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., discussed how these tools can be leveraged to develop a lasting competitive advantage ...
From 2013, NTT Communications has been providing cPaaS service, SkyWay. Its customer’s expectations for leveraging WebRTC technology are not only typical real-time communication use cases such as Web conference, remote education, but also IoT use cases such as remote camera monitoring, smart-glass, and robotic. Because of this, NTT Communications has numerous IoT business use-cases that its customers are developing on top of PaaS. WebRTC will lead IoT businesses to be more innovative and address...
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, will provide a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to ...
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business - from apparel to energy - is being rewritten by software. From planning to development to management to security, CA creates software that fuels transformation for companies in the applic...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, will discuss th...
Recently, IoT seems emerging as a solution vehicle for data analytics on real-world scenarios from setting a room temperature setting to predicting a component failure of an aircraft. Compared with developing an application or deploying a cloud service, is an IoT solution unique? If so, how? How does a typical IoT solution architecture consist? And what are the essential components and how are they relevant to each other? How does the security play out? What are the best practices in formulating...
Given the popularity of the containers, further investment in the telco/cable industry is needed to transition existing VM-based solutions to containerized cloud native deployments. The networking architecture of the solution isolates the network traffic into different network planes (e.g., management, control, and media). This naturally makes support for multiple interfaces in container orchestration engines an indispensable requirement.
In his session at @ThingsExpo, Arvind Radhakrishnen discussed how IoT offers new business models in banking and financial services organizations with the capability to revolutionize products, payments, channels, business processes and asset management built on strong architectural foundation. The following topics were covered: How IoT stands to impact various business parameters including customer experience, cost and risk management within BFS organizations.
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
While some vendors scramble to create and sell you a fancy solution for monitoring your spanking new Amazon Lambdas, hear how you can do it on the cheap using just built-in Java APIs yourself. By exploiting a little-known fact that Lambdas aren’t exactly single-threaded, you can effectively identify hot spots in your serverless code. In his session at @DevOpsSummit at 21st Cloud Expo, Dave Martin, Product owner at CA Technologies, will give a live demonstration and code walkthrough, showing how ...
SYS-CON Events announced today that Elastifile will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Elastifile Cloud File System (ECFS) is software-defined data infrastructure designed for seamless and efficient management of dynamic workloads across heterogeneous environments. Elastifile provides the architecture needed to optimize your hybrid cloud environment, by facilitating efficient...